Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells

Journal of the National Cancer Institute

Volumn 88, Issue 18, 1996, Pages 1285-1296

  St Croix, Brad ^a,b   Rak, Janusz W ^a,b   Kapitain, Sean ^a,b   Sheehan, Capucine ^a,b   Graham, Charles H ^c   Kerbel, Robert S ^a,b,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; HYALURONIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOGENIC ACTIVITY; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYME ANALYSIS; FEMALE; MOUSE; NONHUMAN;

EID: 0029783842     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.18.1285     Document Type: Article

References (75)

1. Baumgartner G, Baumgartner M, Bernhart M, Talth G, Beck A, Hentschel E, et al. Hyaluronidase as supplement to cytostatic chemotherapy. A pilot study. J Exp Clin Cancer Res 1985;4:279-91.
2. Baumgartner G, Fortelny A, Zanker KS, Kroczek R. Phase I study in chemoresistant loco-regional malignant disease with hyaluronidase. Reg Cancer Treat 1988;1:55-8.
3. Maier U, Baumgartner G. Metaphylactic effect of Mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial. J Urol 1989;141:529-30.
4. Lehnert M, Liu R, Salmon SE. Hyaluronidase (HYase) enhances drug toxicity on clusters/colonies of P388 cells in clonogenic assay (abstract). Proc Am Assoc Cancer Res 1989;30:abstr No. 2286.
5. Baumgartner G, Zanker KS, Horaczek A. Hyaluronidase (hyal) as an additive drug in chemoresistant malignant diseases (abstract). Proc ASCO 1987;6:abstract No. 126.
6. Liu R, Cox J, Salmon S. Hyaluronidase enhances the in vitro cytotoxicity of 5-fluorouracil (abstract). In Vitro 1987;23:abstract No. 10.
7. Beckenlehner K, Bannke S, Spruss T, Bernhardt G, Schonenberg H, Schiess W. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J Cancer Res Clin Oncol 1992;118:591-6.
8. Kohno N, Ohnuma T, Truog P. Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality. J Cancer Res Clin Oncol 1994;120:293-7.
9. Spruss T, Bernhardt G, Schonenberger H, Schiess W. Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol 1995;121:193-202.
10. Houghton PJ, Kaye SB. Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. J NIH Res 1994;6:55-61.
11. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990;247:1457-61.
12. Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA, et al. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer Res 1990;50:7634-40.
13. Schecter RL, Woo A, Duong M, Batist G. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. Cancer Res 1991;51:1434-42.
14. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 1993;90:3294-8.
15. Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ, Kerbel RS. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to alkylating agents [see comment citations in Medline]. J Natl Cancer Inst 1994;86:975-82.
16. Durand RE. Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. J Natl Cancer Inst 1986;77:247-52.
17. Durand RE. Distribution and activity of antineoplastic drugs in a tumor model. J Natl Cancer Inst 1989;81:146-52.
18. Durand RE. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother Pharmacol 1990;26:198-204.
19. Kerr DJ, Kaye SB. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol 1987;19:1-5.
20. Erlanson M, Daniel-Szolgay E, Carlsson J. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother Pharmacol 1992;29:343-53.
21. Bullock G, Tang C, Tourkina E, Ibrado AM, Lutzky J, Huang Y, et al. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycylo-phosphamide-induced programmed cell death or apoptosis is human myeloid leukemia cells. Exp Hematol 1993;21:1640-7.
22. Davidoff AN, Mendelow BV. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide. Exp Hematol 1993;21: 922-7.
23. Hoffman RM. In vitro assays for chemotherapy sensitivity. Crit Rev Oncol Hematol 1993;15:99-111.
24. Miller BE, Miller FR, Heppner GH. Factors affecting growth and drug sensitivity of mouse mammary tumor lines in collagen gel cultures. Cancer Res 1985;45:4200-5.
25. Kwok TT, Twentyman PR. The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs - an in vitro study using EMT6 multicellular spheroids. Int J Cancer 1985;35:675-82.
26. Dertinger H, Hulser D. Increased radioresistance of cells in cultured multicell spheroids. I. Dependence on cellular interaction. Radiat Environ Biophys 1981;19:101-7.
27. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988;240:177-84.
28. Olive PL, Banath JP, Evans HH. Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging. Br J Cancer 1993;67:522-30.
29. Underhill CB, Toole BP. Receptors for hyaluronate on the surface of parent and virus-transformed cell lines: binding and aggregation studies. Exp Cell Res 1981;131:419-23.
30. Underbill CB. Interaction of hyaluronate with the surface of simian virus 40-transformed 3T3 cells: aggregation and binding studies. J Cell Sci 1982;56:177-89.
31. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-13.
32. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991;64:867-9.
33. Goldberg RL, Toole BP. Hyaluronate inhibition of cell proliferation. Arthritis Rheum 1987;30:769-78.
34. Alho AM, Underhill CB. The hyaluronate receptor is preferentially expressed on proliferating epithelial cells. J Cell Biol 1989;108:1557-65.
35. Brecht M, Mayer U, Schlosser E, Prehm P. Increased hyaluronate synthesis is required for fibroblast detachment and mitosis. Biochem J 1986;239:445-50.
36. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994;180:53-66.
37. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991;174:859-66.
38. Sy MS, Guo YJ, Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J Exp Med 1992;176:623-7.
39. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 1991;41:6660-7.
40. Zhang L, Underhill CB, Cher L. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res 1995;55:428-33.
41. Hall CL, Yang B, Yang X, Zhang S, Turley M, Samuel S, et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995;82:19-26.
42. Sano Y, Hoshino T, Bjerkvig R, Deen DF. The relative resistance of non-cycling cells in 9L multicellular spheroids to spirohydantoin mustard. Eur J Cancer Clin Oncol 1983;19:1451-6.
43. Deen DF, Hoshino T, Williams ME, Nomura K, Bartle PM. Response of 9L tumor cells in vitro to spirohydantoin mustard. Cancer Res 1979; 39:4336-40.
44. Briffod M, Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Gilles F, et al. Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis. Cytometry 1992;13: 250-8.
45. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelenat H, Pouillait P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 1993;29A:1843-8.
46. Spyratos F, Briffod M, Tubiana-Hulin M, Andrieu C, Mayras C, Pallud C, et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up. Cancer 1992;69:470-5.
47. D'Incalci M, Torti L, Damia G, Erba E, Morasca L, Garattini S. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide. Cancer Res 1983;43:5647-80.
48. Ferrari A, Damia G, Erba E, Rossi C, Mandelli R, D'Incalci M. Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin. Int J Cancer 1989;43:1091-7.
49. Jackel M, Kopf-Maier P. Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother Pharmacol 1991;27:464-71.
50. Wennerberg J, Aim P, Biorklund A, Killander D, Langstrom E, Trope C. Cell cycle perturbations in heterotransplanted squamous-cell carcinoma of the head and neck after mitomycin C and cisplatin treatment, Int J Cancer 1984;33:213-22.
51. DeWys WD. A quantitative model for the study of the growth and treatment of a tumor and its metastases with correlation between proliferative state and sensitivity to cyclophosphamide. Cancer Res 1972;32:367-73.
52. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978;62:1117-33.
53. Braunschweiger PG, Schiffer LM. Therapeutic implications of cell kinetic changes after cyclophosphamide treatment in spontaneous and transplantable mammary tumors. Cancer Treat Rep 1978;62:727-36.
54. Epifanova OI. Differential sensitivity of proliferating and resting cells to anti-tumor drugs and its probable causes. In: Lapis K. Jeney A. editors. Regulation and control of cell proliferation. Budapest: Akademia Kiado, 1984:434-57.
55. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995;267:891-3.
56. Bates RC, Buret A, van Helden DF, Horton MA, Burns GF. Apoptosis induced by inhibition of intercellular contact. J Cell Biol 1994;125:403-15.
57. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-26.
58. Meredith JE Jr, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-61.
59. Darzynkiewicz Z, Traganos F. RNA content and chromatin structure in cycling and noncycling cell populations studied by flow cytometry. In: Padilla G, McCarty K, editors. Genetic expression in the cell cycle. New York: Academic Press, 1982:103-25.
60. Rossini M, Lin JC, Baserga R. Effects of prolonged quiescence on nuclei and chromatin of WI-38 fibroblasts. J Cell Physiol 1975;88:1-11.
61. Olive PL, Durand RE. Effect of intercellular contact on DNA conformation, radiation-induced DNA damage, and mutation in Chinese hamster V79 cells. Radiat Res 1985;101:94-101.
62. Mendonca MS, Rodriguez A, Alpen EL. Differential repair of potentially lethal damage in exponentially growing and quiescent 9L cells. Radial Res 1990;122:38-43.
63. Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 1994;13:121-38.
64. Barcellos-Hoff MH, Marton LJ, Deen DF. Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells. Cancer Res 1990;50:3551-5.
65. Dikomey E. Induction and repair of DNA strand breaks in X-irradiated proliferating and quiescent CHO cells. Int J Radial Biol 1990;57:1169-82.
66. Tannock IF. Tumor growth and cell kinetics. In: Tannock IF, Hill RP, editors. The basic science of oncology. Toronto: Pergamon Press, 1987: 140-59.
67. Meyer JS. Cell kinetic measurements of human tumors. Hum Pathol 1982;13:874-7.
68. Osborne CK. DNA flow cytometry in early breast cancer: a step in the right direction [editorial]. J Natl Cancer Inst 1989;81:1344-5.
69. Remvikos Y, Beuzeboc P, Zajdela Z, Voillemot N, Magdelenat H, Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989; 81:1383-7.
70. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 1992;213:681-3.
71. Remvikos Y, Mosseri V, Zajdela A, Fourquet A, Durand JC, Pouillart P, et al. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann N Y Acad Sci 1993;698:193-203.
72. Sulkes A, Livingston RB, Murphy WK. Tritiated thymidine labeling index and response inhuman breast cancer. J Natl Cancer Inst 1979;62:513-5.
73. Hietanen P, Blomqvist C, Wasenius VM, Niskanen E, Franssila K, Nordling S. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 1995;71:1029-32.
74. Kerbel RS, Rak J, Kobayashi H, Man MS, St Croix B, Graham CH. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harb Symp Quant Biol 1994;59: 661-72.
75. Kerbel RS, St Croix B, Rak J, Graham CH. Is there a role for "anti-adhesives" as chemosensitizers in the treatment of solid tumors by chemotherapy? Bull l'Institut Pasteur 1995;92:248-56.